Lancet Oncology, 20, 1273-1285 Lancet oncology, 20(9), 1273-1285. Elsevier Science The Lancet Oncology, 20(9), 1273-1285 PORTEC study group 2019, ' Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3) : patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial ', The Lancet Oncology, vol. 20, no. 9, pp. 1273-1285 . https://doi.org/10.1016/S1470-2045(19)30395-X The Lancet Oncology Lancet Oncology, 20(9), 1273-1285. ELSEVIER SCIENCE INC Lancet Oncology, 20, 9, pp. 1273-1285
International Journal of Radiation Oncology-Biology-Physics, 109(4), 975-986. ELSEVIER SCIENCE INC International Journal of Radiation Oncology, Biology, Physics, 109, 975-986 International Journal of Radiation Oncology Biology Physics, 109(4), 975-986. Elsevier Science International Journal of Radiation Oncology, Biology, Physics, 109(4), 975-986. ELSEVIER SCIENCE INC International Journal of Radiation Oncology, Biology, Physics, 109, 4, pp. 975-986 International journal of radiation oncology, biology, physics, 109(4), 975-986. Elsevier
Elyashiv, O, Ledermann, J, Parmar, G, Farrelly, L, Counsell, N, Feeney, A, El-khouly, F, Macdonald, I, Neto, A, Arthur-darkwa, E, Burnett, E, Jayson, G C, Mileshkin, L, Gourley, C & Nicum, S 2020, ' ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy ', International Journal of Gynecological Cancer, pp. ijgc-2020-002073 . https://doi.org/10.1136/ijgc-2020-002073